Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial， pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

在高危III期黑色素瘤完全切除后帕博利珠单抗对比安慰剂辅助治疗的3期EORTC 1325-MG/Keynote-054试验中，复发患者的交叉和帕博利珠单抗再挑战

作者：Alexander M. Eggermont， et al.摘要号：9500

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

比较高剂量干扰素或伊匹木单抗与帕博利珠单抗治疗高危已切除黑色素瘤的III期随机试验S1404的最终OS和RFS分析

作者：Kenneth F. Grossmann， et al.

摘要号：9501

Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.

纳武利尤单抗联合抗LAG3抗体relatlimab新辅助和辅助治疗可切除III期黑素瘤患者

作者：Rodabe N. Amaria， et al.

摘要号：9502

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

Relatlimab联合纳武利尤单抗对比纳武利尤单抗一线治疗晚期黑色素瘤：III期RELATIVITY-047（CA224-047）试验的首次结果

作者：Evan J. Lipson， et al

摘要号：9503

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

仑伐替尼+帕博利珠单抗治疗PD-1/L1抑制剂进展的晚期黑色素瘤患者：LEAP-004的最新研究结果

作者：Ana M. Arance， et al.

摘要号：9504

Lifileucel (LN-144)， a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.

Lifileucel（LN-144），一种冷冻保存的自体肿瘤浸润淋巴细胞（TIL）治疗晚期黑色素瘤：评价既往PD-1治疗的影响

作者：James Larkin， et al.

摘要号：9505

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

CheckMate 067：晚期黑素瘤患者6.5年结局

作者：Jedd D. Wolchok， et al.

摘要号：9506

Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.

COLUMBUS研究5年OS：康奈非尼+比米替尼对比维莫非你+康奈非尼治疗BRAF V600突变黑色素瘤患者的随机3期试验

作者：Reinhard Dummer， et al.

摘要号：9507

Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).

抗PD-1脑协作（ABC研究）的5年OS：纳武利尤单抗或纳武利尤单抗+伊匹木单抗治疗黑色素瘤脑转移患者的随机2期研究

作者：Georgina V. Long， et al

摘要号：9508